Using ML to decode human biology and accelerate drug discovery
In the last 8 years, Recursion has built one of the largest proprietary biological data sets on earth. Every week the company runs up to 2.2 million experiments, using ML to screen biological images for disease and run simulations of potential treatments. Their vision is to decrease the rate of failure in the drug discovery process, generate novel insights to lead to better medicines, and ultimately, save the lives of patients.
Join Jaclyn Rice Nelson, CEO of Tribe AI, and Ben Mabey, CTO of Recursion, as they discuss:
How ML is driving change in drug discovery and development
The Recursion approach – using biological images and deep learning to accelerate drug discovery at scale
Building an applied AI company based on research
Moving from IC researcher and data scientist to CTO of a public biotech company